Cellzome secures second alliance with GSK

Cellzome Inc said that it has secured a new drug discovery deal with GlaxoSmithKline under which the companies will seek to identify small-molecule drugs against epigenetic targets. Cellzome will receive €33 million upfront.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom